Skip to main content

Table 3 Clinical and laboratory findings dependent on TKTL1 expression status

From: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

  TKTL1/GUS ≤
Median (n = 17)
TKTL1/GUS >
Median (n = 16)
P value
Median age (n = 33): 61 years 63 59 p = 0.89
Clinical tumour stage uN negative n = 5 (29%) uN negative n = 5 (31%) p = 1.0
  uN positive n = 12 (71%) uN positive n = 11 (69%)  
Pathological tumour stage (n = 32) ypT0N0 n = 1 ypT0N0 n = 2 p = 0.69
  ypT1-2N0 n = 6 ypT1-2N0 n = 6  
  ypT3-4N0 n = 6 ypT3-4N0 n = 2  
  ypTanyN+ n = 4 ypTanyN+ n = 5  
CEA (median) 2.1 4.25 p = 0.074
CA 19-9 10 23 p = 0.18
VEGFR1 (median) 0.4125; n = 10 0.1034; n = 16 p = 0.19
VEGFR2 (median) 0.4413; n = 16 0.8241; n = 16 p = 0.11
Survivin (n = 30) (median) 6.4; n = 17 8.5; n = 13 p = 0.081
KRAS mutated (n = 14/33) n = 6 (35%) n = 8 (50%) p = 0.49
Loss of PTEN (n = 2/30) n = 1/16 (6%) n = 1/14 (7%) p = 1.0
Local recurrence n = 0 (0%) n = 2 (12.5%) p = 0.22
Metastasis during follow up n = 1 (6%) n = 9 (56%) p = 0.0024
Median DFS ∞ (months) 39 23 p = 0.017
Death n = 2 (12%) n = 4 (25%) p = 0.39
Median Survival (months) 39 26 p = 0.26
  1. ∞ disease-free survival